Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
ACS Medicinal Chemistry Letters2013Vol. 4(3), pp. 358–362
Citations Over TimeTop 10% of 2013 papers
Tara Rheault, John Stellwagen, George M. Adjabeng, Keith R. Hornberger, Kimberly G. Petrov, Alex G. Waterson, Scott H. Dickerson, Robert A. Mook, Sylvie Laquerre, Alastair J. King, Olivia W. Rossanese, Marc R. Arnone, Kimberly N. Smitheman, Laurie S. Kane-Carson, Chao Han, Ganesh S. Moorthy, Katherine G. Moss, David Uehling
Abstract
Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-Raf(V600E) mutated enzyme has been observed in a number of human tumors, including melanomas. Herein we report the discovery and biological evaluation of GSK2118436, a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-Raf(V600E) human melanoma. GSK2118436 was identified as a development candidate, and early clinical results have shown significant activity in patients with B-Raf mutant melanoma.
Related Papers
- → Dabrafenib in advanced melanoma with BRAF V600E mutation(2014)11 cited
- → Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report(2023)2 cited
- Dabrafenib Therapy and BRAF and G6PD Genotype(2017)
- → EP1.14-44 Lung Adenocarcinoma with a Rare BRAF V600E K601_W604del Mutation Responded to Dabrafenib Plus Trametinib Treatment: A Case Report(2019)
- → Supplementary Material from A Secondary Mutation in <i>BRAF</i> Confers Resistance to RAF Inhibition in a <i>BRAF</i><sup>V600E</sup>-Mutant Brain Tumor(2023)